Dominican RepublicTuberculosis profile
Population  2015 11 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.49 (0.27–0.77) 4.6 (2.6–7.3)
Mortality (HIV+TB only) 0.38 (0.12–0.78) 3.6 (1.1–7.4)
Incidence  (includes HIV+TB) 6.3 (4.7–8.3) 60 (44–78)
Incidence (HIV+TB only) 1.6 (1–2.3) 15 (9.5–21)
Incidence (MDR/RR-TB)** 0.28 (0.16–0.39) 2.7 (1.5–3.7)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.23 (0.079–0.38) 2 (1–3) 2.3 (1.1–3.4)
Males 0.33 (0.2–0.45) 3.8 (2.8–4.7) 4.1 (3–5.2)
Total 0.56 (0.38–0.74) 5.8 (4.8–6.8) 6.3 (4.7–8.3)
TB case notifications, 2015  
Total cases notified 4 690
Total new and relapse 4 504
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 79%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 69%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 71% (55–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.14 (0.08–0.23)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 843 24%
          - on antiretroviral therapy 817 97%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  170
(110–240)
Estimated % of TB cases with MDR/RR-TB 3% (1.5–4.6) 12% (6.9–17)  
% notified tested for rifampicin resistance 7% 47% 570
MDR/RR-TB cases tested for resistance to second-line drugs   3
Laboratory-confirmed cases MDR/RR-TB: 104, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 114, XDR-TB: 4
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 83% 2 770
Previously treated cases, excluding relapse, registered in 2014 58% 200
HIV-positive TB cases, all types, registered in 2014 69% 291
MDR/RR-TB cases started on second-line treatment in 2013 73% 94
XDR-TB cases started on second-line treatment in 2013 75% 4
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 18%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 15
Funding source: 63% domestic, 23% international, 14% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-06 Data: www.who.int/tb/data